newsfilter
← Latest News
Business Wire·

Star Therapeutics Announces $200 Million Private Financing to Advance Pipeline of Best-in-Disease Therapies

  • Star Therapeutics announced a $200 million private financing to advance preclinical programs into clinical trials & expand its pipeline.
  • The financing was co-led by OrbiMed & Janus Henderson Investors, with participation from multiple other healthcare investors.
  • This funding follows the July 2026 acquisition of Star subsidiary Vega Therapeutics by Incyte for up to $2 billion.
  • Star's team has invented four first-in-class therapies, including one approved drug & three others currently in Phase 3 development.
  • In September 2026, Star's spinout Electra Therapeutics became a publicly traded company on NASDAQ.
  • Proceeds will support the development of next-generation therapies & the advancement of the company's current programs into the clinic.